Notably, VEGF concentration abated in the presence of Bortezomib in the case of Patient 4, while it was unaffected in the case of Patient 5, once again paralleling the sensitivity to the drug of MM cells (Figure 4B). This evidence concerns the gene VEGFA and Miyoshi myopathy.